Premium
EARLY EXPERIENCE WITH POSTOPERATIVE ADJUVANT CHEMORADIATION FOR RECTAL CARCINOMA: FOCUS ON MORBIDITY
Author(s) -
Chen F. C.,
Mackay J. R.,
Woods R. J.,
Collopy B. T.,
Fink R. J.,
Guiney M. J.
Publication year - 1995
Publication title -
australian and new zealand journal of surgery
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.111
H-Index - 51
eISSN - 1445-2197
pISSN - 0004-8682
DOI - 10.1111/j.1445-2197.1995.tb00547.x
Subject(s) - medicine , adjuvant , surgery , rectal carcinoma , carcinoma , adjuvant therapy , colorectal cancer , chemotherapy , cancer
The morbidity of postoperative adjuvant chemoradiation for primary extraperitoneal rectal carcinoma is documented in this ongoing study. Patients who presented electively for resection with ACPS Dukes' B and C extraperitoneal rectal carcinoma during the period January 1990 to June 1993 were studied. Twenty patients received postoperative adjuvant chemoradiation. At a mean follow up of 32.6 months (s. d. 7.1), three of the 20 patients who received combined adjuvant chemoradiation reported no side effects. In 10 patients (50%) complications were classified as minor. In the remaining seven patients (35%) major complications of therapy occurred. There were no deaths. These early results highlight the morbidity of postoperative adjuvant chemoradiation that has been presumed but not documented.